ATE499445T1 - Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b - Google Patents

Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b

Info

Publication number
ATE499445T1
ATE499445T1 AT99966122T AT99966122T ATE499445T1 AT E499445 T1 ATE499445 T1 AT E499445T1 AT 99966122 T AT99966122 T AT 99966122T AT 99966122 T AT99966122 T AT 99966122T AT E499445 T1 ATE499445 T1 AT E499445T1
Authority
AT
Austria
Prior art keywords
kappa
modulation
ubiquitin ligase
human ubiquitin
compositions
Prior art date
Application number
AT99966122T
Other languages
English (en)
Inventor
Anthony M Manning
Frank Mercurio
Sharon Amit
Yinon Ben-Neriah
Matti Davis
Ada Hatzubai
Iris Lavon
Avraham Yaron
Original Assignee
Signal Pharm Llc
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc, Yissum Res Dev Co filed Critical Signal Pharm Llc
Application granted granted Critical
Publication of ATE499445T1 publication Critical patent/ATE499445T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT99966122T 1998-12-10 1999-12-09 Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b ATE499445T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21006098A 1998-12-10 1998-12-10
PCT/US1999/029371 WO2000034447A2 (en) 1998-12-10 1999-12-09 Human ubiquitin ligase e3 for the modulation of nf-kappa b

Publications (1)

Publication Number Publication Date
ATE499445T1 true ATE499445T1 (de) 2011-03-15

Family

ID=22781444

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99966122T ATE499445T1 (de) 1998-12-10 1999-12-09 Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b

Country Status (12)

Country Link
US (4) US6656713B2 (de)
EP (1) EP1135504B1 (de)
JP (1) JP4633259B2 (de)
KR (2) KR20070050995A (de)
CN (2) CN102816743A (de)
AT (1) ATE499445T1 (de)
AU (2) AU779893B2 (de)
CA (1) CA2354153C (de)
DE (1) DE69943222D1 (de)
ES (1) ES2361660T3 (de)
IL (3) IL143516A0 (de)
WO (1) WO2000034447A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4695735B2 (ja) * 1996-08-26 2011-06-08 シグナル ファーマシューティカルズ， エルエルシー 刺激誘導性Ｉ（κ）Ｂキナーゼ［ＩＫＫ］シグナルソーム
ATE499445T1 (de) * 1998-12-10 2011-03-15 Signal Pharm Llc Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b
AU2001281052A1 (en) * 2000-08-07 2002-02-18 Deltagen, Inc. Transgenic mice containing ubiquitin protein ligase e3 gene disruptions
EP1182251A1 (de) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Verfahren zum Identifizieren von Verbindungen, die die Ubiquitin vermittelte Proteolyse von IkB inhibieren
WO2002050261A2 (en) * 2000-12-18 2002-06-27 Hybrigenics PROTEINS THAT INTERACT WITH βTRCP
US7037936B2 (en) 2002-06-17 2006-05-02 Signal Pharmaceuticals, Llc. Compounds useful for the treatment of cancer, compositions thereof and methods therewith
US20060256599A1 (en) * 2005-03-22 2006-11-16 Malin Patricia J Database of electronically profiled cells and methods for generating and using same
US20100292306A1 (en) * 2005-05-24 2010-11-18 Carlson C George Compositions And Methods For The Treatment Of Muscular Dystrophy
DE602006014519D1 (de) 2005-12-16 2010-07-08 Nat Cancer Ct Peptide zur transglutaminase-hemmung
US20070202593A1 (en) * 2006-02-27 2007-08-30 Research Development Foundation Cell-Targeted IKB and Methods for the Use Thereof
GB201110938D0 (en) * 2011-06-27 2011-08-10 Iti Scotland Ltd Compounds
US20130210875A1 (en) * 2012-02-10 2013-08-15 Macau University Of Science And Technology Novel binding site of IKK-beta
CN117534753B (zh) * 2023-12-07 2024-05-10 北京博奥森生物技术有限公司 一种诱导高性能NF-κB多克隆抗体多肽及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5519003A (en) 1994-02-01 1996-05-21 Board Of Trustees Of The Leland Stanford Junior University WD-40-derived peptides and uses thereof
US5597898A (en) * 1995-02-15 1997-01-28 Yale University NF-κB activation regulatory protein, IκB-β
JP4695735B2 (ja) 1996-08-26 2011-06-08 シグナル ファーマシューティカルズ， エルエルシー 刺激誘導性Ｉ（κ）Ｂキナーゼ［ＩＫＫ］シグナルソーム
US5972674A (en) * 1996-08-26 1999-10-26 Signal Pharmaceuticals, Inc. Stimulus-inducible protein kinase complex and methods of use therefor
US5932425A (en) 1997-02-18 1999-08-03 Signal Pharmaceuticals, Inc. Compositions and methods for modulating cellular NF-κB activation
US5851812A (en) * 1997-07-01 1998-12-22 Tularik Inc. IKK-β proteins, nucleic acids and methods
US6235512B1 (en) * 1997-07-01 2001-05-22 Tularik Inc. IKK-α proteins, nucleic acids and methods
US6242253B1 (en) * 1997-10-09 2001-06-05 Regents Of The University Of California IkB kinase, subunits thereof, and methods of using same
US6573094B1 (en) * 1997-10-16 2003-06-03 Baylor College Of Medicine F-box genes and proteins
FR2774378A1 (fr) * 1998-01-30 1999-07-30 Inst Nat Sante Rech Med PROTEINE HUMAINE BETA-TrCP DE CIBLAGE DES PROTEINES VERS LES VOIES DE DEGRADATION PAR LE PROTEASOME
ATE499445T1 (de) * 1998-12-10 2011-03-15 Signal Pharm Llc Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b
US6280623B1 (en) * 1999-03-23 2001-08-28 Hsien-Chih Ma Differential and continuous separation apparatus with controlled parameters for solids and liquids
US6649654B1 (en) * 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors

Also Published As

Publication number Publication date
JP2002539766A (ja) 2002-11-26
US7414120B2 (en) 2008-08-19
IL143516A0 (en) 2002-04-21
DE69943222D1 (de) 2011-04-07
JP4633259B2 (ja) 2011-02-16
US20040203098A1 (en) 2004-10-14
US20090233855A1 (en) 2009-09-17
US8263326B2 (en) 2012-09-11
IL143516A (en) 2010-11-30
AU2004240212A1 (en) 2005-02-10
US7186503B2 (en) 2007-03-06
WO2000034447A2 (en) 2000-06-15
KR100756689B1 (ko) 2007-09-07
KR20070050995A (ko) 2007-05-16
WO2000034447A8 (en) 2001-07-12
CN1346406A (zh) 2002-04-24
AU2004240212A8 (en) 2005-02-10
WO2000034447A3 (en) 2000-11-09
CN102816743A (zh) 2012-12-12
AU2004240212B2 (en) 2007-12-06
KR20020007284A (ko) 2002-01-26
AU779893B2 (en) 2005-02-17
AU2174000A (en) 2000-06-26
CA2354153C (en) 2011-04-12
EP1135504B1 (de) 2011-02-23
US20030166587A1 (en) 2003-09-04
IL187254A (en) 2010-12-30
CA2354153A1 (en) 2000-06-15
US20070208167A1 (en) 2007-09-06
EP1135504A2 (de) 2001-09-26
WO2000034447A9 (en) 2002-08-29
US6656713B2 (en) 2003-12-02
ES2361660T3 (es) 2011-06-21

Similar Documents

Publication Publication Date Title
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
DE69939864D1 (de) Ppar-gamma modulatoren
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
ATE326239T1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
IL138476A0 (en) Method for treating pharmaceutical compositions by special use of anti-oxidant
ATE253631T1 (de) Eine thrombin-blutfraktion zur verwendung in einem medizinischen verfahren
ATE391177T1 (de) Zusammensetzungen und methoden zur modulierung der zellulären aktivität von nf-kappab
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
ATE255632T1 (de) Immortalisierung bzw. desimmortalisierung von zellen
PL346246A1 (en) Modulating multiple lineage kinase proteins
DE58906239D1 (de) Einrichtung zur Behandlung von Erkrankungen, insbesondere der Sehbahn.
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
DE69910425D1 (de) Neue therapeutische verwendung von nicergoline
WO2002014536A3 (en) Odulating multiple lineage kinase proteins
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
NO984189L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
DE69924385D1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
DE60007864D1 (de) Verwendung von antileukoprotease zur behandlung von endometriose
DE59712374D1 (de) Verwendung von hcc-1 zur behandlung von thrombozytopenien
WO2003023048A3 (en) METHODS FOR DIAGNOSING AND TREATING DISEASES AND CONDITIONS ASSOCIATED WITH PROTEIN KINASE C$g(l)
ATE247467T1 (de) Neue therapeutische verwendung von 1,6-dimethyl- 8beta-hydroxymethyl-10alpha-methoxyergolin
ATE272406T1 (de) Prognose von ptp lar vermittelten krankheiten
UA31270A (uk) Спосіб формування товстокишкового анастомозу
UA32146A (uk) Спосіб оцінки ефективності лікування пародонтита

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties